Estimated Impact of Nirsevimab on the Incidence of Respiratory Syncytial Virus Infections Requiring Hospital Admission in Children < 1 Year, Weeks 40, 2023, to 8, 2024, Spain

Influenza Other Respir Viruses. 2024 May;18(5):e13294. doi: 10.1111/irv.13294.

Abstract

Background: Data from the sentinel surveillance system of severe acute respiratory infections in Spain were used to estimate the impact of administration of nirsevimab to children born from 1 April 2023 onwards.

Methods: Estimated RSV hospitalisations in < 1-year-olds during weeks 40, 2023, to 8, 2024, were compared to the number that would be expected after accounting for the background change in RSV circulation in the 2023/24 season, compared to 2022/23.

Results: We estimated 9364-9875 RSV hospitalisations less than expected, corresponding to a 74%-75% reduction.

Keywords: SARI; burden; impact; respiratory infections; respiratory syncitial virus; surveillance.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Antiviral Agents* / therapeutic use
  • Female
  • Hospitalization* / statistics & numerical data
  • Humans
  • Incidence
  • Infant
  • Infant, Newborn
  • Male
  • Respiratory Syncytial Virus Infections* / drug therapy
  • Respiratory Syncytial Virus Infections* / epidemiology
  • Respiratory Syncytial Virus, Human
  • Sentinel Surveillance
  • Spain / epidemiology

Substances

  • Antiviral Agents
  • Antibodies, Monoclonal, Humanized